Verge Genomics is a company that develops a drug discovery platform for neurodegenerative diseases. It was founded in 2015 by Alice Zhang and Jason Chen. Verge Genomics has received funding from OS Fund, WuXi AppTec, and ALS Investment Fund. The company is headquartered in San Francisco, California, United States.
Verge Genomics's computational biology and artificial intelligence platform is able to generate novel drug compounds to target genes involved in neurodegenerative diseases. The platform is designed to construct new therapeutics for diseases that are caused by multiple gene anomalies. The company uses datasets collected from human tissue samples of patients with diseases such as Parkinson's and amyotrophic lateral sclerosis (ALS). Several new therapeutics for ALS developed by Verge Genomics have passed preclinical trials.
